Paid Clinical Trials in Fairway, KS

As of June 2026, 85 paid clinical trials are recruiting in Fairway, Kansas. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 25, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

84 clinical trials

↓ Download CSV

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

for Acute Myeloid Leukemia

22 locations incl. Orange

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 75

Code: NCT05886049·Phase 1·Recruiting

Apply to this trial

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

for Polymyositis, Dermatomyositis

43 locations incl. Phoenix

Sponsor: AstraZeneca

Sex: All·Age: 18 - 75

Code: NCT06455449·Phase 3·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

for Light Chain (AL) Amyloidosis

18 locations incl. Berkeley

Sponsor: Nexcella Inc.

Sex: All·Age: 18 - 120

Code: NCT06097832·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of IBI363 in Subjects with Advanced Solid Malignancies

for Melanoma

9 locations incl. San Francisco

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Sex: All·Age: 18+

Code: NCT06281678·Phase 2·Recruiting

Apply to this trial

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

384 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting

Apply to this trial

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

for Myotonic Dystrophy Type 1 (DM1)

8 locations incl. San Carlos

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 18 - 64

Code: NCT06185764·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for Advanced Solid Tumors With KRAS G12C Mutations

15 locations incl. La Jolla

Sponsor: Frontier Medicines Corporation

Sex: All·Age: 18+

Code: NCT06244771·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

for Metastatic Colorectal Carcinoma

22 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05803382·Phase 1·Recruiting

Apply to this trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

148 locations incl. Dothan

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05952557·Phase 3·Recruiting

Apply to this trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

for Advanced Malignant Solid Neoplasm

23 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691491·Phase 1, Phase 2·Recruiting

Apply to this trial

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

for cGVHD

32 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05919511·Recruiting

Apply to this trial

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

for Relapsed or Resistant Acute Leukaemias

5 locations incl. Tampa

Sponsor: Lin BioScience, Inc

Sex: All·Age: 18 - 120

Code: NCT05756322·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting

Apply to this trial

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

for Generalized Myasthenia Gravis

2 locations incl. Fairway

Sponsor: University of Missouri-Columbia

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06064695·Recruiting

Apply to this trial

Alzheimer's Disease Neuroimaging Initiative 4

for Mild Cognitive Impairment

59 locations incl. Birmingham

Sponsor: University of Southern California

Sex: All·Age: 55 - 90·Accepts healthy volunteers

Code: NCT05617014·Enrolling By Invitation

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

for Myositis

47 locations incl. Glendale

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT05895786·Phase 3·Recruiting

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

454 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting

Apply to this trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

for Advanced Malignant Solid Neoplasm

36 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05327010·Phase 2·Recruiting

Apply to this trial

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

for Type2Diabetes

36 locations incl. Huntsville

Sponsor: Brigham and Women's Hospital

Sex: All·Age: 40 - 80

Code: NCT05390892·Phase 4·Recruiting

Apply to this trial

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

17 locations incl. Tampa

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05172245·Phase 1·Recruiting

Apply to this trial

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

for Congenital Myotonic Dystrophy

4 locations incl. Los Angeles

Sponsor: Virginia Commonwealth University

Sex: All·Age: Up to 59 Months

Code: NCT05224778·Recruiting

Apply to this trial

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

for Lung Cancer

2 locations incl. Fairway

Sponsor: Jun Zhang, MD, PhD

Sex: All·Age: 18 - 110

Code: NCT05332925·Recruiting

Apply to this trial

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

for Amyloid Plaque

13 locations incl. Phoenix

Sponsor: AC Immune SA

Sex: All·Age: 35 - 85

Code: NCT05462106·Phase 1, Phase 2·Recruiting

Apply to this trial

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

for NSCLC Stage IV

Drug: Atezolizumab

2 locations incl. Fairway

Sponsor: University of Kansas Medical Center

Sex: All·Age: 18+

Code: NCT04467723·Phase 1, Phase 2·Recruiting

Apply to this trial

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

for Adenocarcinoma of the Colon

472 locations incl. Fairbanks

Sponsor: NRG Oncology

Sex: All·Age: 45 - 70

Code: NCT05080673·Recruiting

Apply to this trial

CureDuchenne Link®: A Resource for Research

for Duchenne Muscular Dystrophy

10 locations incl. Little Rock

Sponsor: CureDuchenne

Sex: All·Age: 4 Weeks+

Code: NCT04972604·Recruiting

Apply to this trial

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

for Recurrent Ovarian High Grade Serous Adenocarcinoma

27 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT04633239·Phase 1·Recruiting

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

451 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting

Apply to this trial

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

for Locally Advanced Pancreatic Adenocarcinoma

Drug: Peposertib

44 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04172532·Phase 1, Phase 2·Recruiting

Apply to this trial

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

for Advanced Solid Tumors

2 locations incl. Fairway

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12 - 120

Code: NCT04222413·Phase 1·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

for Advanced EGFR Positive Solid Tumor

3 locations incl. Los Angeles

Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD

Sex: All·Age: 18+

Code: NCT04412616·Phase 1·Recruiting

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

49 locations incl. Birmingham

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting

Apply to this trial

HEALEY ALS Platform Trial - Master Protocol

for Amyotrophic Lateral Sclerosis

81 locations incl. Phoenix

Sponsor: Merit E. Cudkowicz, MD

Sex: All·Age: 18+

Code: NCT04297683·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

Drug: sigvotatug vedotin

105 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting

Apply to this trial

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

for Acute Myeloid Leukemia

2 locations incl. Jacksonville

Sponsor: Celyad Oncology SA

Sex: All·Age: 18+

Code: NCT04167696·Phase 1·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

for Lower Respiratory Tract Infection

23 locations incl. Duarte

Sponsor: Ansun Biopharma, Inc.

Sex: All·Age: All ages

Code: NCT03808922·Phase 3·Recruiting

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

Drug: Cabozantinib

580 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting

Apply to this trial